Lung cancer's enduring global significance necessitates ongoing advancements in
diagnostics and therapeutics. Recent spotlight on proteomic and genetic biomarker research …

Dysregulated MET signaling plays an important role in lung oncogenesis, tumor growth and
invasiveness. It may occur through various mechanisms, such as MET overexpression or …

Background The gefitinib resistance mechanism in non-small cell lung cancer (NSCLC)
remains unclear, albeit exosomal circular RNA (circRNA) is known to possibly play a vital …

Two new series of symmetric (1a-h) and asymmetric (2a-l) 1, 4-DHP derivatives were
designed, synthesised, and evaluated as anticancer agents. In vitro anticancer screening of …

Background Non-small cell cancer (NSCLC) patients with concomitant epidermal growth
factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of …

Background: Proteasome 26S subunit, ATPase gene (PSMC) family members play a critical
role in regulating protein degradation and are essential for tumor development. However …

The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin
plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR) …

With the development of technologies, multiple primary lung cancer (MPLC) has been
detected more frequently. Although large-scale genomics studies have made significant …

Introduction Echinoderm microtubule-associated protein-like 4 (EML4)-Anaplastic
Lymphoma Kinase (ALK) rearrangements occur in 3% to 7% of lung adenocarcinomas and …

Precision cancer medicine has changed the treatment paradigm of patients with non-small
cell lung cancer (NSCLC) with specific molecular aberrations. A major challenge is …